An observational study in Severe Asthma, sponsored by University of British Columbia. Recruiting at 12 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University of British Columbia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Asthma by University of British Columbia — 5 open to participants now, 5 under way, none of them phase 3. Asthma · University of British Columbia.
Among the 20 studies in Asthma by University of British Columbia, this one is one of 3 that started in 2018, is one of 6 observational ones, and was the 14th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →5 of the 20 studies in Asthma by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Ages 19–80 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages up to 6 mo · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 18–55 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 714 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 52 across the 14 interventional studies, 511 across the 6 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
1 of the studies in Asthma by University of British Columbia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07653347University of British ColumbiaInfant RSV Immunity Study | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Asthma by University of British Columbia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The International Severe Asthma Registry is a global initiative looking to ensure that the care of people with severe asthma will continue to improve by collecting detailed information about the health and treatment of as many people with the disease as possible. The study will gather anonymized longitudinal real-life data for participants with severe asthma for five years. The purpose of the registry is to track the progress of participants and determine how well they are responding to treatment. Medical research using data from the registry will give the investigators a better understanding of severe asthma and help the investigators develop and improve the care and treatment for severe asthma participants. The Canadian cohort of the registry will collect information from Canadian participants with severe asthma across seven different sites.
Study staff will collect medical information through reviewing participant medical charts and interviewing participants about their health/asthma. The information collected includes birth date, gender, ethnicity, height/weight, body mass index, medical history (smoking history and exacerbation history), current and past asthma related medications, and any recent test results available pertaining to blood work, lung function, allergen skin prick, and imaging. This information will be collected at the baseline visit, and then once a year at a follow up visit, for five years (total of five visits).
Participants will be assigned a unique study number to protect the confidentiality of their personal health care information. All study data will be de-identified and then stored in a secure information management system, hosted at the study sponsor, Optimum Patient Care Global Limited in Cambridge, United Kingdom. Participant identities will always be kept confidential and will not be included in any research that is published. Data collected across the Canadian sites will be used to find ways to improve asthma treatments in Canada, to report on current patterns of managing severe asthma in Canada, to identify different sub-groups of severe asthma, and to carry out various medical research to understand asthma better and develop new treatments.
Research records and health or other source records may be inspected in the presence of the Principal Investigator or by representatives of the University of British Columbia's Clinical Research Ethics Board for the purpose of monitoring the research. No information or records that disclose participants' identities will be published without subject consent, nor will any information or records that disclose participants' identities be removed or released without subject consent unless required by law.
The study population will be selected from respirology/pulmonary clinics across Canada. Participants will be identified and recruited by the study investigators and study staff based on their clinical presentation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Participants with mild to moderate asthma
Participants with severe asthma classified at GINA Step 4 and uncontrolled in terms of their symptoms and exacerbations or GINA Step 5.
Blood eosinophil counts
10\^9/L
Time frame: Past 12 months
Blood Immunoglobulin E (IgE) counts
kilo unit/L
Time frame: Past 12 months
Fractional exhaled nitric oxide level
parts per billion
Time frame: Past 12 months
Start and end dates of oral corticosteroid medication
Day/Month/Year for start and end dates if available
Time frame: Prior to baseline visit
Asthma Control
Assessed through the Global Initiative for Asthma (GINA) Questionnaire
Time frame: Past 4 weeks
Start and end dates of biologic medications such as anti-interleukin-5, anti-immunoglobulin E, or anti-interleukin-4 treatments (if relevant)
Day/Month/Year for start and end dates if available
Time frame: Prior to baseline visit
Reason for switching biologic medication (if relevant)
Options include: lack of clinical efficacy, side effects, biologic access restriction, and patient preference
Time frame: Past 12 months
Start and end dates of all asthma related inhaled medications
Day/Month/Year for start and end dates if available
Time frame: Prior to baseline visit
Number of asthma exacerbations requiring rescue steroids
Severe asthma exacerbations are defined as events that require urgent action (rescue steroids) by the participant and physician to prevent a serious outcome
Time frame: Past 12 months
Number of emergency room visits for asthma
Total number of visits
Time frame: Past 12 months
Number of hospital admissions for asthma
Total number of admissions
Time frame: Past 12 months
Spirometry test results for Forced Vital Capacity (FVC)
Pre- and post-bronchodilator FVC results in litres
Time frame: Past 12 months
Spirometry test results for Forced Expiratory Volume in One Second (FEV1)
Pre- and post-bronchodilator FEV1 results in litres
Time frame: Past 12 months
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2018 (actual). Primary completion is estimated for Dec 2027, 109 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →